scispace - formally typeset
J

Jing Dong

Researcher at Baylor College of Medicine

Publications -  76
Citations -  3502

Jing Dong is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Lung cancer & Single-nucleotide polymorphism. The author has an hindex of 33, co-authored 75 publications receiving 3020 citations. Previous affiliations of Jing Dong include Medical College of Wisconsin & Nanjing Medical University.

Papers
More filters
Journal ArticleDOI

Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.

Qing Lan, +133 more
- 01 Dec 2012 - 
TL;DR: It is observed that there is no evidence of association for lung cancer at 15q25 in never-smoking women in Asia, providing strong evidence that this locus is not associated with lung cancer independent of smoking.
Journal ArticleDOI

A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1

TL;DR: A genome-wide association study in 3,279 individuals of Chinese descent found two new susceptibility loci for non-cardia gastric cancer at 5p13.1 and 3q13.31, and confirmed previously reported associations of rs2294008 and rs2976392 on 8q24, rs4072037 on 1q22 and rs13042395 on 20p13 with non- Cardia gastrics cancer susceptibility in the Han Chinese population.
Journal ArticleDOI

Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus.

TL;DR: Serum miRNAs are differentially expressed between GDM women and controls and could be candidate biomarkers for predicting GDM.
Journal ArticleDOI

Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls

TL;DR: The four-miRNA signature from serum may serve as a non-invasive prediction biomarker for breast cancer risk prediction based on a two-stage case-control analysis and the combination of miRNA-484 and mi RNA-191 is proposed as endogenous control for serum miRNA detection, at least for most common cancers.
Journal ArticleDOI

Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma

TL;DR: A meta‐analysis revealed that four miRNAs could be used as preclinical biomarkers for HCC screening and the expression profile of the eight‐miRNA panel can be used to discriminate HCC patients from cancer‐free controls, and the four‐mi RNA panel (alone or combined with AFP) could be a blood‐based early detection biomarker for H CC screening.